The Berlin-based research team first had the idea for a new kind of drug against atrial fibrillation more than ten years ago. They have been supported in creating the spin-off and carrying out initial clinical trials by BMBF and private investors.
The US-American manufacturer Proteintech is expanding its portfolio of next generation antibody technology via acquisition. The Munich-based start-up ChromoTek is the market leader in particularly small and versatile antibodies.
The start-up team have managed to impress with their business plan for a diagnostics company. The highly-sensitive diagnostics allow the parallel expression analysis of individual cells and can contribute to tailor-made approaches to therapy.
Allein in Deutschland erleiden jedes Jahr rund 270.000 Menschen einen Schlaganfall. Bei der Therapie-Wahl stehen Ärztinnen und Ärzte unter enormem Druck. Ein Computermodell soll sie unterstützen und passgenaue Entscheidungen ermöglichen.
Just four months after starting to look for a SARS-CoV-2 vaccine, the biotech firm BioNTech and the US Pfizer pharmaceutical group have announced the selection of a highly-promising main candidate and the start of the global phase 2/3 approval trial.
High-quality peptide combinations made from alternative agricultural waste for healthy nutrition
Designer recombinases platform for precise genome surgery
Aminolipine for formaldehyde-free fixing of biological materials
Gene therapy to fight epilepsy
T-cell immunotherapy to fight blood cancers
New nano-sized carrier system for chemotherapeutics
Platform technology for highly parallel single-cell genetic analysis of tumour tissue
User data is collected from you whenever you visit this site. To find out how the Federal Ministry of Education and Research (BMBF) handles your data and the purpose of processing your data please refer to our statement on data protection.